South Korean biotech firm Samsung Biologics has recently provided antibody treatments for COVID-19 to U.S.-based firm Eli Lilly for mass production.
According to industry watchers on Wednesday, Samsung Biologics has already produced a small amount of treatment at its labs in South Korea in cooperation with Eli Lilly, and has sent this to the U.S. to be mass produced.
Samsung Biologics made the agreement with Eli Lilly back in May, and also has an agreement with another global pharmaceutical firm.
Back in July, another industry leader SK bioscience signed an agreement to produce a COVID-19 vaccine with British-Swedish bio-giant AstraZeneca before also signing with U.S. firm Novavax.

Reporter :


Source Link

This page is made available thanks to China Press Release by Topic News

Leave a Reply

Your email address will not be published.